ARYA Sciences Acquisition Corp V
Liquidated 2023-07-03- CIK 1852432
- ARYE
- IPO 2021-07-14
- $153M trust
- 52 filings
- IPO Size
- $150M
- raised at the IPO
- Trust
- $153M
- as of 2023-03-31
- Current Status
- Failed
- from its latest filing
- IPO Year
- 2021
- year it listed
Filings, by quarter
52 filings over 13 quarters; violet bars carry a milestone
- 21 Q1: 1 filing
- 21 Q2: 1 filing
- 21 Q3: 22 filings
- 21 Q4: 1 filing
- 22 Q1: 7 filings
- 22 Q2: 1 filing
- 22 Q3: 1 filing
- 22 Q4: 2 filings
- 23 Q1: 5 filings
- 23 Q2: 5 filings
- 23 Q3: 5 filings
- 23 Q4: 0 filings
- 24 Q1: 1 filing
- S-1 filed 21 Q1
- IPO 21 Q3
- Liquidated 23 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
ARYA Sciences Acquisition Corp V is a blank check company formed to effect an initial business combination, with an intended focus on healthcare and healthcare-related industries, particularly life sciences and medical technology companies in North America or Europe.
Investment Focus
Healthcare, Biopharmaceuticals, Technology
Geographic Focus
North America, Europe
Key Information
As the filings state it
- IPO Date
- 2021-07-14
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- Failed Date
- 2023-07-03
- SPAC Ticker
- ARYE
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The sponsor is affiliated with Perceptive Advisors, a healthcare-focused investment firm. The team includes Perceptive Advisors' founders and executives, including Joseph Edelman, Adam Stone, Michael Altman and Konstantin Poukalov, with experience in healthcare investing, life sciences and prior SPAC business combinations.